Showing 3211-3220 of 4166 results for "".
- France First in EU to Reimburse Hoya MiYOSMART Lens for Childhood Myopiahttps://modernod.com/news/france-first-in-eu-to-reimburse-hoya-miyosmart-lens-for-childhood-myopia/2482856/France will begin reimbursing Hoya Vision Care’s MiYOSMART myopia control spectacle lenses for eligible children starting July 1. This move makes France as the first country in the European Union to provide public coverage for the lenses.
- New York Eye and Ear Infirmary of Mount Sinai Opens First Comprehensive Center for Refractive Solutions in New Yorkhttps://modernod.com/news/new-york-eye-and-ear-infirmary-of-mount-sinai-opens-first-comprehensive-center-for-refractive-solutions-in-new-york/2482855/The New York Eye and Ear Infirmary of Mount Sinai (NYEE) has announced the launch of the Center for Refractive Solutions, a facility dedicated to comprehensive vision correction services. Located at 310 East 14th Street in Lower Manhattan, the newly renovated
- FDA Approves Genentech’s Susvimo for Diabetic Retinopathyhttps://modernod.com/news/fda-approves-genentechs-susvimo-for-diabetic-retinopathy/2482815/Genentech has received FDA approval for Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR). The approval makes Susvimo the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with one refill ever
- EYE-GO Secures Strategic Investment from Topcon Healthcarehttps://modernod.com/news/eye-go-secures-strategic-investment-from-topcon-healthcare/2482807/EYE-GO, a Danish MedTech company, today announced that Topcon Healthcare, Inc will become a strategic investor in their company. According to EYE-GO, the collaboration reflects a shared vision to revolutionize chronic eye disease management through evidence-
- Bausch + Lomb Launches Zenlens CHROMA HOA in the UShttps://modernod.com/news/bausch-lomb-launches-zenlens-chroma-hoa-in-the-us/2482802/Bausch + Lomb announced the US launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos an
- Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Resultshttps://modernod.com/news/isarna-therapeutics-presents-positive-phase-2-better-trial-final-results-at-arvo-2025/2482797/Isarna Therapeutics presented final positive results from its phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on May 6. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, shared data
- Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-datasets-on-the-potential-of-its-anti-vegf-therapy-dosed-twice-yearly-for-wet-amd/2482790/Valitor announced data from VLTR-559, its long-acting anti-VEGF biologic in development for its wet age-related macular degeneration (AMD) treatment, and its multivalent polymer (MVP) technology platform, were presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annua
- Johnson & Johnson to Present New Scientific Data on Acuvue Oasys Max 1-Day, Tecnis Odyssey, and a Purely Refractive Next Generation EDF IOL at ARVOhttps://modernod.com/news/johnson-johnson-to-present-new-scientific-data-on-acuvue-oasys-max-1-day-tecnis-odyssey-and-a-purely-refractive-next-generation-edf-iol-at-arvo/2482783/Johnson & Johnson will present new data on several of its latest innovations through 35+ posters and oral presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 4-8. New in-vitro methodology shows that Acuvue Oasys Max&nb
- Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVOhttps://modernod.com/news/opus-genetics-announces-presentation-of-opgx-lca5-gene-therapy-data-at-arvo/2482782/Opus Genetics announced 1-year results from adult patients treated in the ongoing phase 1/2 Study of its lead gene therapy candidate OPGx-LCA5. These results were presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), taking place May 4
- Topcon Healthcare Acquires RetInSight to Accelerate AI-Powered Imaging in Eye Carehttps://modernod.com/news/topcon-healthcare-acquires-retinsight-to-accelerate-ai-powered-imaging-in-eye-care/2482777/Topcon Healthcare announced the acquisition of Vienna, Austria-based RetInSight. The move advances Topcon Healthcare’s vision of Healthcare from the Eye, enhancing access to intelligent diagnostics that increase access to high-quality eye care, reduce healthcare costs, and improve